ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, updated the Phase 1 study results of IBI343, a novel anti-CLDN18.2 ADC, for the treatment of advanced pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
With extended follow-up and more mature data on progression-free survival (PFS) and overall survival (OS), IBI343 has demonstrated promising therapeutic efficacy in patients with CLDN18.2-positive advanced pancreatic cancer. These encouraging results suggest the potential of IBI343 in this challenging-to-treat malignancy. Supported by these robust clinical findings, IBI343 has been granted Breakthrough Therapy Designation (BTD) by China's National Medical Products Administration (NMPA). Concurrently, the Phase 1 clinical trial of IBI343 is also being conducted in the United States, where the drug candidate has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA).
Pancreatic cancer is one of the most aggressive malignancies worldwide. Most patients are diagnosed in the middle and late stages and often develop resistance to standard chemotherapy, resulting in a 5-year survival rate of less than 10%1. According to the GLOBOCAN 2022 statistics2, there are approximately 510,000 new cases and 467,000 deaths globally from pancreatic cancer each year, with China accounting for 120,000 new cases and 110,000 deaths annually.
This Phase 1/1b study is a multi-regional, dose escalation and expansion clinical trial (NCT05458219). Preliminary data were presented at ASCO 2025 and ESMO Asia 2024 and the updated results from the study's dose-expansion cohort were presented at the 2025 ASCO as follows:
As of March 14, 2025, a total of 83 patients with pancreatic cancer had received at least one dose of IBI343 with a median follow-up time of 11.1 months.
As the data cutoff date, in patients with CLDN18.2 1+2+3+≥60% expression treated at the 6mg/kg dose (N=44), the confirmed overall objective response rate (cORR) was 22.7% and the disease control rate (DCR) was 81.8%. The median progression-free survival (mPFS) was 5.4 months, and the median overall survival (mOS) was 9.1 months. Among them, 17 patients had received only one line of prior treatment, achieving a mPFS of 5.4 months and a mOS of 12.1 months; and 18 patients had received two lines of prior treatment, the mPFS was 5.3 months and the mOS was 9.1 months.
The updated safety results demonstrated the favorable safety profile of IBI343 with a consistently low rate of gastrointestinal toxicity and no new safety signals. 98.8% of the patients experienced treatment-emergent adverse events (TEAEs), with the most common TEAEs being anemia, neutrophil count decreased, and white blood cell count decreased. Notably, no ≥ grade 3 nausea and vomiting occurred.
Professor Xianjun Yu from Fudan University Cancer Hospital, said, "Pancreatic cancer is one of the most malignant tumors of the digestive tract. Most patients are already in the advanced stage when diagnosed, and the 5-year survival rate is only about 10%1. Currently, chemotherapy is still the main first- and second-line treatment for advanced pancreatic cancer. The clinical options for second-line treatment are particularly limited, with a chemotherapy response rate of only 6-16%, median progression free survival of 2 to 5 months, and a median survival of approximately 6 to 9 months3, representing an urgent clinical need. With longer follow-up, the mature PFS and OS data from the latest IBI343 update demonstrate promising therapeutic potential, suggesting a breakthrough in this difficult-to-treat malignancy."
Dr. Hui Zhou, Senior Vice President of Innovent, said, "We are pleased to present an oral update on IBI343's clinical data at this year's ASCO conference. With the unique Fc-silent antibody design, stable linker and potent TOPO1i payload, IBI343 is the first ADC candidate to show encouraging efficacy and a favorable safety profile in the treatment of advanced pancreatic cancer. We hope to continue advancing the clinical trials of IBI343 for pancreatic cancer patients. Innovent will leverage its unique strengths in R&D innovation and clinical translation to develop a new generation of globally competitive oncology - focused innovative pipeline to benefit patients worldwide.."
About IBI343（Anti-CLDN18.2 ADC）
IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. IBI343 binds to the CLDN18.2-expressing tumor cells, the CLDN18.2 dependent ADC internalization will occur and the drug is released resulting in DNA damage and eventually apoptosis of the tumor cells. The freed drug can also diffuse across the plasma membrane to reach and kill the neighboring cells, resulting in "bystander killing effect".
As an innovative TOPO1i ADC, IBI343 has demonstrated tolerable safety and encouraging efficacy signals in Phase 1 clinical studies. The therapeutic potential of IBI343 is currently being explored in tumor types such as gastric and pancreatic cancer.
The Phase 3 trial of IBI343 for advanced gastric / gastroesophageal junction adenocarcinoma is now recruiting patients. The relevant indication has been included in China's NMPA breakthrough therapy list.
IBI343's Phase 1 trial for advanced pancreatic ductal adenocarcinoma is enrolling patients in an multi-regional study. This indication has received Fast Track designation from the FDA and been included in the NMPA's BTD list.
About Innovent Biologics
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement:
1. Innovent Biologics does not recommend the use of unapproved drugs/indications.
2. Ramucirumab injection (Ciranza®), selpercatinib capsules (Ritu®) and pirtobrutinib tablets (Capra®) were developed by Eli Lilly and Company
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
References
1 Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33. doi: 10.3322/caac.21708.
2 Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.
3 Jemal A, Bray F, Center MM, et al. Global cancer stastics. CA Cancer J Clin, 2011, 61(2): 69-90.
View original content:https://www.prnewswire.com/news-releases/asco-2025-oral-presentation-innovent-biologics-announces-updated-data-of-ibi343-novel-anti-cldn18-2-adc-from-the-phase-1-clinical-study-in-patients-with-advanced-pancreatic-cancer-302470512.html
SOURCE Innovent Biologics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Rhône Valley's Côtes du Rhône and Côtes du Rhône Villages AOCs Increase Focus on Wine Tourism
The vibrant spirit and unique experiences put the region in a prime position to draw in visitors, both domestic and international, even further NEW YORK, June 4, 2025 /PRNewswire/ -- Inter Rhône, the organization that represents the Rhône Valley Vineyards AOCs, is happy to share that the Côtes du Rhône and Côtes du Rhône Villages AOCs, two significant appellations of the Rhône Valley, are concentrating on new and exciting wine tourism events and activities for consumers to explore this historic, dynamic part of the region. According to the French Ministry of Tourism, France is the world's leading tourist destination. The past few years have seen continued growth, with 2023 and 2024 seeing a record number of over 100 million visitors. The global wine tourism market is also expected to see continued growth over the next 10 years. The Côtes du Rhône, then, is poised to welcome visitors to this one-of-a-kind region: Imagine sipping wine under the sun, surrounded by medieval villages and rolling vineyards - the Côtes du Rhône is the ultimate getaway for adventure seekers, families, foodies, and culture lovers alike. Cultural and Historical WondersThe Côtes du Rhône is rich in history, with four UNESCO World Heritage sites, from the majestic Palais des Papes in Avignon, a 14th-century Gothic palace that once served as the residence of popes, to the Pont du Gard, an ancient Roman aqueduct that stands as a marvel of engineering. Stepping back even further, the Grotte Chauvet 2 cave in Ardèche, an accurate replica of the original Chauvet Caves, showcases prehistoric art that is over 30,000 years old. The stunning wine-producing villages of Séguret, Aiguèze, and La Roque-sur-Cèze truly capture the heart of the Côtes du Rhône with their beautiful scenery. Sip, Savor, RepeatFor epicures, the Côtes du Rhône is home to a wide range of wines, from expressive reds and crisp whites to delicate rosés, paired with local delights like black truffles, creamy goat cheese, and Nyons olives for the ultimate tasting experience. Gastronomic experiences abound in the Côtes du Rhône, including chic bistros and picnics in the vineyards. Festivals, Music, and Good VibesThe Côtes du Rhône is known for its exciting fêtes, from lively music festivals to gourmet food events. Whether tasting through a wine festival or experiencing a traditional celebration, there is always a reason to raise a glass! Nature, but Make It FunFor visitors looking for outdoor adventures, the Côtes du Rhône is full of activities, from cycling through the vineyards on the scenic EuroVelo 17 (aka 'Via Rhôna'), hiking through breathtaking landscapes, to taking a guided wine walk. Sustainability is key here, and the region is dedicated to preserving its natural beauty. Wine Tourism: A New EraWineries here are leaning into consumer interests - moving away from stuffy tastings and shaking things up with even more hands-on experiences, such as blending workshops, themed tastings, sensory tastings, massages in the vineyards, and overnight vineyard stays. The Côtes du Rhône region is appealing to those who are wine newbies, as well as to seasoned connoisseurs, with a wide range of unique experiences and something for everyone. Tourists interested in planning an unforgettable trip to the Côtes du Rhône can for insider tips and must-visit spots. About Côtes du Rhône and Côtes du Rhône Villages AOCsCôtes du Rhône and Côtes du Rhône Villages AOCs are two significant appellations within the Rhône Valley wine region of France, renowned for their diverse and high-quality wines. Côtes du Rhône AOC (Appellation d'Origine Contrôlée) is one of the largest and most renowned appellations in France, covering vast vineyard areas along the Rhône River. It encompasses both the Northern and Southern Rhône regions, allowing for a wide range of grape varieties and wine styles. Produced in 172 communes on rich and varied terroirs, regional Côtes du Rhône is notable for its diversity, its character and a blend that guarantees a quality wine. Côtes du Rhône Villages AOC represents a step up in quality and specificity within the Côtes du Rhône appellation. This designation is reserved for wines that meet stricter production standards and come from specific communes or villages within the Rhône Valley. The regulations limit yields and dictate stricter guidelines for grape growing and winemaking practices, ensuring higher quality standards. Within the Côtes du Rhône Villages AOC, there are also specific villages entitled to append their name to the label, denoting even higher quality standards. There are 21 such villages, each recognized for their unique terroir and historical winemaking traditions. For more information, please visit and for photos, please visit Press Contacts:Erin HealyColangelo & Partnersehealy@ Béatrice MialonInter Rhônebmialon@inter-rhô View original content to download multimedia: SOURCE Inter Rhône Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Business News
44 minutes ago
- Time Business News
Cannabis Use Disorder: Recognizing the Signs of Marijuana Addiction
Cannabis has undergone a dramatic transformation in the public eye—from stigmatized contraband to a widely accepted substance, often marketed as benign or even medicinal. While its therapeutic benefits for certain conditions are legitimate, a less discussed truth persists: cannabis can be addictive. Cannabis Use Disorder (CUD) is a recognized mental health diagnosis with real consequences for those affected. Awareness of its signs is the first step toward meaningful intervention. Understanding the Link Between Stimulants and Attention Disorders Some individuals with ADHD may experience temporary relief from symptoms when using stimulants, but it's important to understand the distinction between medical treatments and harmful substances. Methamphetamine is a powerful and highly addictive stimulant that affects the brain's dopamine system, similar to prescription medications like Adderall,does meth help with adhd which are used to treat ADHD. However, while prescription stimulants are carefully dosed and monitored, meth is illegal and dangerous. Although people may believe meth helps with ADHD, it often leads to severe side effects, addiction, and long-term cognitive damage, making it an unsafe and ineffective treatment option. Defining Cannabis Use Disorder Cannabis Use Disorder is not mere overindulgence. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), it is characterized by a cluster of behavioral, physical, and psychological symptoms reflecting impaired control over use. Individuals with CUD may persist in their consumption despite significant personal, social, or professional disruption. The line between recreational use and disorder is often subtle, obscured by normalization and denial. Dependence develops when the user experiences both tolerance and withdrawal. Tolerance demands higher doses to achieve the desired effect, while withdrawal manifests when cessation leads to discomfort or dysfunction. These signs, when coupled with continued use, form the clinical foundation of addiction. Behavioral and Psychological Signs of Cannabis Addiction The behavioral patterns of CUD frequently begin with increased frequency. What starts as occasional use may escalate to daily or near-daily consumption. Users may express intentions to reduce their intake, only to relapse repeatedly. This cycle of attempted restraint and resumed use signals a loss of control. Psychologically, the individual may exhibit blunted ambition—a phenomenon colloquially dubbed 'amotivational syndrome.' Tasks once pursued with vigor now seem burdensome. Apathy replaces curiosity. Emotionally, cannabis dependency often breeds irritability, anxiety, or even mild paranoia. Thoughts may feel foggy, attention drifts, and short-term memory deteriorates. These symptoms do not exist in isolation; they interact, compounding dysfunction. Physical Indicators of Chronic Cannabis Use Though often viewed as non-threatening, chronic marijuana use can leave a physiological imprint. Inhalation of cannabis—particularly when combusted—can inflame the lungs, leading to chronic bronchitis-like symptoms: persistent coughing, wheezing, and phlegm production. Sleep architecture is also affected. While cannabis may initially induce drowsiness, prolonged use disrupts REM cycles, resulting in non-restorative sleep or even insomnia. Appetite patterns may also become dysregulated. Some individuals experience excessive hunger (the classic 'munchies'), while others notice erratic food intake. Withdrawal from cannabis, though often milder than that of opioids or alcohol, is nonetheless significant. Users may report tremors, restlessness, irritability, intense cravings, or gastrointestinal distress within 24–72 hours of cessation. Impact on Daily Functioning and Relationships As dependence deepens, the effects on daily life become undeniable. Academic performance may slip as concentration wanes. Job responsibilities are neglected. Timeliness and reliability erode. In some cases, individuals abandon pursuits they once valued, such as hobbies or creative endeavors. Social relationships often bear the brunt. Users may withdraw from loved ones, preferring solitude or only associating with fellow users. Deception around use becomes common—hiding cannabis, minimizing quantity, or becoming defensive when questioned. Responsibilities—whether domestic, financial, or familial—are routinely postponed or disregarded altogether. Risk Factors for Developing Cannabis Use Disorder Not everyone who uses cannabis will develop CUD. Certain factors, however, raise the risk. A family history of addiction suggests a genetic vulnerability. Co-occurring mental health conditions, particularly anxiety, depression, and attention disorders, increase susceptibility. The age of initial use plays a pivotal role. Adolescents and young adults are especially at risk, as their brains are still undergoing critical developmental changes. Additionally, today's cannabis strains, often cultivated to yield high THC concentrations, possess greater addictive potential than earlier iterations. Social environments that normalize or glamorize heavy use can reinforce unhealthy patterns. When to Seek Help and Available Treatment Options One of the most insidious aspects of CUD is the denial that often accompanies it. Users may dismiss their behavior as harmless or deny the extent of their dependency. However, once the patterns begin to interfere with quality of life, it is time to take action. Therapeutic interventions are available and effective. Cognitive Behavioral Therapy (CBT) is commonly used to address underlying thought patterns that drive compulsive use. Motivational Enhancement Therapy (MET) helps increase internal drive toward recovery. In some cases, contingency management—offering rewards for sobriety—has shown promise. Long-term recovery may also involve group therapy, mindfulness practices, and lifestyle restructuring. The journey is rarely linear. Relapse can occur. But with proper support, lasting recovery is achievable. Understanding the Differences Between Two Dangerous Drugs While meth and crack are both powerful and highly addictive stimulants, they are not the same. Meth, short for methamphetamine, is a synthetic drug often found in pill or powder form, while crack is a smokable form of cocaine made by processing cocaine hydrochloride with baking soda or ammonia. Each affects the brain differently—meth releases large amounts of dopamine, causing long-lasting highs,are meth and crack the same whereas crack produces intense but short-lived euphoria. Although both substances are harmful, meth tends to cause more severe long-term neurological damage. Understanding the differences between meth and crack is essential for recognizing their unique risks. Conclusion Cannabis Use Disorder is a legitimate, clinically recognized condition that merits serious attention. It is not confined to stereotypes or extremes. It can affect high-functioning professionals, students, and creatives alike. Recognizing the signs early allows for timely intervention and more successful outcomes. With the right treatment and support, individuals struggling with CUD can regain clarity, motivation, and control over their lives. Compassion—not judgment—is the foundation of healing. TIME BUSINESS NEWS
Yahoo
an hour ago
- Yahoo
Look Before You Rent webinars
SYRACUSE. N.Y. (WSYR-TV) — The city of Syracuse is set to host two technical assistance webinars involving a tutorial on 'Look Before You Rent,' which is an online tool to help you become more educated on rental properties in Syracuse. This online map includes all the information you need about rentals. Including how to search by address or neighborhood to discover a property's status on the City's Rental Registry, Certificate of Compliance programs and any code violations or other property information. The webinars are scheduled for Tuesday, June 10, from 1:30 to 2:15 p.m. and Wednesday, June 11, from 5:30 to 6:15 p.m. Staff members will show attendees how to access and use the tool. There will also be times to ask questions and give feedback. To participate, you must register here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
